Logo image of ADN1.DE

ADESSO SE (ADN1.DE) Stock Fundamental Analysis

Europe - FRA:ADN1 - DE000A0Z23Q5 - Common Stock

94.5 EUR
-0.2 (-0.21%)
Last: 11/14/2025, 7:00:00 PM
Fundamental Rating

5

Overall ADN1 gets a fundamental rating of 5 out of 10. We evaluated ADN1 against 70 industry peers in the IT Services industry. ADN1 has only an average score on both its financial health and profitability. ADN1 is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

In the past year ADN1 was profitable.
ADN1 had a positive operating cash flow in the past year.
In the past 5 years ADN1 has always been profitable.
In the past 5 years ADN1 always reported a positive cash flow from operatings.
ADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

Looking at the Return On Assets, with a value of 2.34%, ADN1 is doing worse than 61.43% of the companies in the same industry.
The Return On Equity of ADN1 (11.09%) is comparable to the rest of the industry.
With a Return On Invested Capital value of 5.34%, ADN1 is not doing good in the industry: 65.71% of the companies in the same industry are doing better.
ADN1 had an Average Return On Invested Capital over the past 3 years of 3.16%. This is significantly below the industry average of 11.69%.
The 3 year average ROIC (3.16%) for ADN1 is below the current ROIC(5.34%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.34%
ROE 11.09%
ROIC 5.34%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ADN1.DE Yearly ROA, ROE, ROICADN1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

ADN1's Profit Margin of 0.96% is on the low side compared to the rest of the industry. ADN1 is outperformed by 65.71% of its industry peers.
ADN1's Profit Margin has declined in the last couple of years.
ADN1 has a worse Operating Margin (3.04%) than 67.14% of its industry peers.
ADN1's Operating Margin has declined in the last couple of years.
ADN1 has a Gross Margin of 85.66%. This is in the better half of the industry: ADN1 outperforms 78.57% of its industry peers.
In the last couple of years the Gross Margin of ADN1 has remained more or less at the same level.
Industry RankSector Rank
OM 3.04%
PM (TTM) 0.96%
GM 85.66%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
ADN1.DE Yearly Profit, Operating, Gross MarginsADN1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ADN1 is destroying value.
The number of shares outstanding for ADN1 has been reduced compared to 1 year ago.
Compared to 5 years ago, ADN1 has more shares outstanding
ADN1 has a better debt/assets ratio than last year.
ADN1.DE Yearly Shares OutstandingADN1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ADN1.DE Yearly Total Debt VS Total AssetsADN1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

ADN1 has an Altman-Z score of 3.60. This indicates that ADN1 is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.60, ADN1 is in the better half of the industry, outperforming 78.57% of the companies in the same industry.
ADN1 has a debt to FCF ratio of 4.22. This is a neutral value as ADN1 would need 4.22 years to pay back of all of its debts.
The Debt to FCF ratio of ADN1 (4.22) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.89 indicates that ADN1 is somewhat dependend on debt financing.
ADN1 has a Debt to Equity ratio of 0.89. This is in the lower half of the industry: ADN1 underperforms 62.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF 4.22
Altman-Z 3.6
ROIC/WACC0.95
WACC5.65%
ADN1.DE Yearly LT Debt VS Equity VS FCFADN1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 1.26 indicates that ADN1 should not have too much problems paying its short term obligations.
ADN1 has a Current ratio (1.26) which is in line with its industry peers.
ADN1 has a Quick Ratio of 1.26. This is a normal value and indicates that ADN1 is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ADN1 (1.26) is better than 65.71% of its industry peers.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.26
ADN1.DE Yearly Current Assets VS Current LiabilitesADN1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 1204.39% over the past year.
The earnings per share for ADN1 have been decreasing by -15.02% on average. This is quite bad
Looking at the last year, ADN1 shows a quite strong growth in Revenue. The Revenue has grown by 12.81% in the last year.
The Revenue has been growing by 23.60% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)1204.39%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%42.38%
Revenue 1Y (TTM)12.81%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%12.43%

3.2 Future

Based on estimates for the next years, ADN1 will show a very strong growth in Earnings Per Share. The EPS will grow by 40.29% on average per year.
ADN1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.91% yearly.
EPS Next Y105.03%
EPS Next 2Y80.21%
EPS Next 3Y64.94%
EPS Next 5Y40.29%
Revenue Next Year10.46%
Revenue Next 2Y10.44%
Revenue Next 3Y10.29%
Revenue Next 5Y10.91%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADN1.DE Yearly Revenue VS EstimatesADN1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B 2.5B
ADN1.DE Yearly EPS VS EstimatesADN1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 31.19, ADN1 can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of ADN1 indicates a slightly more expensive valuation: ADN1 is more expensive than 60.00% of the companies listed in the same industry.
ADN1's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 25.89.
Based on the Price/Forward Earnings ratio of 15.96, the valuation of ADN1 can be described as correct.
The rest of the industry has a similar Price/Forward Earnings ratio as ADN1.
ADN1 is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.59, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 31.19
Fwd PE 15.96
ADN1.DE Price Earnings VS Forward Price EarningsADN1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

ADN1's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. ADN1 is cheaper than 68.57% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ADN1 is valued a bit cheaper than 61.43% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.46
EV/EBITDA 5.97
ADN1.DE Per share dataADN1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 100 200 300

4.3 Compensation for Growth

ADN1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ADN1's earnings are expected to grow with 64.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.3
PEG (5Y)N/A
EPS Next 2Y80.21%
EPS Next 3Y64.94%

4

5. Dividend

5.1 Amount

With a yearly dividend of 0.82%, ADN1 is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 3.87, ADN1 has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.36, ADN1's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.82%

5.2 History

The dividend of ADN1 is nicely growing with an annual growth rate of 15.65%!
Dividend Growth(5Y)15.65%
Div Incr Years5
Div Non Decr Years6
ADN1.DE Yearly Dividends per shareADN1.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

ADN1 pays out 33.51% of its income as dividend. This is a sustainable payout ratio.
The dividend of ADN1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP33.51%
EPS Next 2Y80.21%
EPS Next 3Y64.94%
ADN1.DE Yearly Income VS Free CF VS DividendADN1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ADN1.DE Dividend Payout.ADN1.DE Dividend Payout, showing the Payout Ratio.ADN1.DE Dividend Payout.PayoutRetained Earnings

ADESSO SE

FRA:ADN1 (11/14/2025, 7:00:00 PM)

94.5

-0.2 (-0.21%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)08-14 2025-08-14
Earnings (Next)11-12 2025-11-12
Inst Owners19.2%
Inst Owner ChangeN/A
Ins Owners49.34%
Ins Owner ChangeN/A
Market Cap617.09M
Revenue(TTM)2.06B
Net Income(TTM)19.75M
Analysts81.54
Price Target127.79 (35.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.82%
Yearly Dividend0.94
Dividend Growth(5Y)15.65%
DP33.51%
Div Incr Years5
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.92%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.11%
EPS NY rev (3m)-7.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.41%
Valuation
Industry RankSector Rank
PE 31.19
Fwd PE 15.96
P/S 0.3
P/FCF 11.46
P/OCF 7.3
P/B 3.46
P/tB 16.99
EV/EBITDA 5.97
EPS(TTM)3.03
EY3.21%
EPS(NY)5.92
Fwd EY6.27%
FCF(TTM)8.24
FCFY8.72%
OCF(TTM)12.94
OCFY13.69%
SpS315.32
BVpS27.28
TBVpS5.56
PEG (NY)0.3
PEG (5Y)N/A
Graham Number43.12
Profitability
Industry RankSector Rank
ROA 2.34%
ROE 11.09%
ROCE 12.16%
ROIC 5.34%
ROICexc 5.9%
ROICexgc 8.47%
OM 3.04%
PM (TTM) 0.96%
GM 85.66%
FCFM 2.61%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ROICexc(3y)4.06%
ROICexc(5y)6.01%
ROICexgc(3y)6.65%
ROICexgc(5y)10.11%
ROCE(3y)7.2%
ROCE(5y)10.26%
ROICexgc growth 3Y-20.34%
ROICexgc growth 5Y-12.01%
ROICexc growth 3Y-21.84%
ROICexc growth 5Y-11.01%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
F-Score8
Asset Turnover2.44
Health
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF 4.22
Debt/EBITDA 1.19
Cap/Depr 43.51%
Cap/Sales 1.49%
Interest Coverage 4.84
Cash Conversion 63.53%
Profit Quality 272.63%
Current Ratio 1.26
Quick Ratio 1.26
Altman-Z 3.6
F-Score8
WACC5.65%
ROIC/WACC0.95
Cap/Depr(3y)52.06%
Cap/Depr(5y)49.68%
Cap/Sales(3y)2.64%
Cap/Sales(5y)2.54%
Profit Quality(3y)790.41%
Profit Quality(5y)538.39%
High Growth Momentum
Growth
EPS 1Y (TTM)1204.39%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%42.38%
EPS Next Y105.03%
EPS Next 2Y80.21%
EPS Next 3Y64.94%
EPS Next 5Y40.29%
Revenue 1Y (TTM)12.81%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%12.43%
Revenue Next Year10.46%
Revenue Next 2Y10.44%
Revenue Next 3Y10.29%
Revenue Next 5Y10.91%
EBIT growth 1Y69.72%
EBIT growth 3Y-13.12%
EBIT growth 5Y5.01%
EBIT Next Year305.17%
EBIT Next 3Y80.92%
EBIT Next 5Y43.99%
FCF growth 1Y295.38%
FCF growth 3Y40.19%
FCF growth 5Y49.54%
OCF growth 1Y14594.7%
OCF growth 3Y32.14%
OCF growth 5Y37.69%

ADESSO SE / ADN1.DE FAQ

What is the ChartMill fundamental rating of ADESSO SE (ADN1.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to ADN1.DE.


What is the valuation status of ADESSO SE (ADN1.DE) stock?

ChartMill assigns a valuation rating of 5 / 10 to ADESSO SE (ADN1.DE). This can be considered as Fairly Valued.


What is the profitability of ADN1 stock?

ADESSO SE (ADN1.DE) has a profitability rating of 4 / 10.


What is the valuation of ADESSO SE based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ADESSO SE (ADN1.DE) is 31.19 and the Price/Book (PB) ratio is 3.46.


Is the dividend of ADESSO SE sustainable?

The dividend rating of ADESSO SE (ADN1.DE) is 4 / 10 and the dividend payout ratio is 33.51%.